Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 4 1Phase 2 1Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 52Neoplasms 28Neoplasm Metastasis 26Colorectal Neoplasms 26Recurrence 22Ovarian Neoplasms 22Pancreatic Neoplasms 21Prostatic Neoplasms 20Breast Neoplasms 20Squamous Cell Carcinoma of Head and Neck 19Melanoma 18Glioblastoma 16Lymphoma, Large B-Cell, Diffuse 14Lung Neoplasms 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Multiple Myeloma 13Lymphoma, Non-Hodgkin 13Endometrial Neoplasms 13Triple Negative Breast Neoplasms 12Colonic Neoplasms 12Carcinoma, Renal Cell 11Stomach Neoplasms 10Leukemia, Myeloid, Acute 10Glioma 10Gastrointestinal Neoplasms 10Rectal Neoplasms 9Lymphoma, Follicular 9Lymphoma 9Head and Neck Neoplasms 9Small Cell Lung Carcinoma 8

Interventions

resiniferatoxin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Cancer Pain × 30 days × Clear all
NCT02522611 2026-06-01

Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain

National Institutes of Health Clinical Center (CC)

Phase 1/2 Not yet recruiting
30 enrolled

Cancer Pain, Pain, Intractable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡